NOT YET RECRUITING
NCT06809751
Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy
The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are:
1. How does melatonin affect central macula thickness in CSCR?
2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR.
Participants will:
1. Take melatonin or placebo twice a day for one month
2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests
3. Keep a diary of their symptoms
Gender: All
Ages: 18 Years - Any
Central Serous Chorioretinopathy
Melatonin
Ocular Diseases
+2